Your browser is no longer supported. Please, upgrade your browser.
Settings
UROV Urovant Sciences Ltd. daily Stock Chart
UROV [NASD]
Urovant Sciences Ltd.
Index- P/E- EPS (ttm)-3.69 Insider Own75.30% Shs Outstand29.44M Perf Week-4.76%
Market Cap229.63M Forward P/E- EPS next Y-4.01 Insider Trans- Shs Float7.49M Perf Month6.70%
Income-111.30M PEG- EPS next Q-1.10 Inst Own21.90% Short Float3.18% Perf Quarter-25.50%
Sales- P/S- EPS this Y-259.00% Inst Trans-3.82% Short Ratio4.18 Perf Half Y49.71%
Book/sh2.47 P/B3.16 EPS next Y4.00% ROA-185.30% Target Price24.00 Perf Year-
Cash/sh2.90 P/C2.69 EPS next 5Y- ROE-269.80% 52W Range4.05 - 14.49 Perf YTD18.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.17% Beta-
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low92.36% ATR0.63
Employees39 Current Ratio8.30 Sales Q/Q- Oper. Margin- RSI (14)47.93 Volatility6.83% 8.52%
OptionableNo Debt/Eq0.18 EPS Q/Q22.30% Profit Margin- Rel Volume0.33 Prev Close7.99
ShortableYes LT Debt/Eq0.18 EarningsJun 13 AMC Payout- Avg Volume57.07K Price7.80
Recom1.80 SMA20-1.84% SMA50-1.61% SMA200-15.45% Volume19,067 Change-2.38%
Mar-15-19Initiated SunTrust Buy $24
Mar-11-19Initiated H.C. Wainwright Buy $28
Oct-22-18Initiated JP Morgan Overweight $21
Oct-22-18Initiated Jefferies Buy $19
Jun-20-19 08:25AM  Urovant Sciences Ltd. (NASDAQ:UROV): Immense Growth Potential? Simply Wall St.
Jun-13-19 04:05PM  Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019 Business Wire -6.09%
02:30PM  Urovant Sciences Ltd. to Host Earnings Call ACCESSWIRE
Jun-06-19 08:00AM  Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019 Business Wire
Jun-03-19 08:00AM  Urovant Sciences to Present at Annual Roivant Pipeline Day Business Wire
May-30-19 08:00AM  Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-06-19 08:00AM  Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting Business Wire
Apr-29-19 08:00AM  Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting Business Wire
Mar-27-19 08:00AM  Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia Business Wire -5.08%
Mar-19-19 04:09PM  Here's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data Motley Fool -20.63%
08:00AM  Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder Business Wire
Mar-18-19 04:05PM  Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder Business Wire
Mar-07-19 08:00AM  Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference Business Wire
Mar-06-19 08:00AM  Urovant Sciences Appoints James Robinson to its Board of Directors Business Wire
Feb-26-19 08:14PM  Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-22-19 05:20PM  Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital Business Wire
Feb-13-19 04:05PM  Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018 Business Wire
Feb-06-19 08:00AM  Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results Business Wire
Jan-15-19 08:00AM  Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019 Business Wire
Jan-03-19 08:00AM  Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome Business Wire
Jan-02-19 08:00AM  Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire +6.22%
Dec-19-18 08:00AM  Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference Business Wire
Nov-19-18 08:00AM  Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference Business Wire
Nov-12-18 04:05PM  Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update Business Wire
Nov-08-18 08:00AM  Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder Business Wire
Nov-05-18 08:00AM  Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results Business Wire -6.32%
Nov-01-18 08:00AM  Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology Business Wire -6.47%
Oct-11-18 06:41PM  Andreas Halvorsen Discloses Stake in Urovant Sciences GuruFocus.com
Sep-27-18 05:24PM  [$$] Gormley's Take: Urovant Sciences IPO Draws Attention to Urology Market The Wall Street Journal
Sep-26-18 11:00PM  Urovant Sciences Ltd. Announces Pricing of Initial Public Offering PR Newswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.